A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Inclusion Criteria: * Males and females of non-childbearing potential ≥50 years of age (at the time of signing the informed consent document) with documented IPF * Diagnosis of IPF based on current ATS/ERS guidelines * Usual interstitial pneumonia (UIP) pattern on HRCT and/or UIP pattern on histopathology (ie surgical lung biopsy), and * Exclusion of known causes of interstitial lung disease (such as environmental exposure, connective tissue disease and drug toxicity), Or * UIP pattern on surgical lung biopsy required if HRCT is inconsistent with UIP Exclusion Criteria: * FVC : \< 50% predicted \>90% predicted * DLco:\< 25% predicted \>90% predicted * Saturated oxygen (SpO2) of \<92% (room air \[sea level\] at rest). SpO2 of \< 88% (room air \[≥ 5,000 feet above sea level (1524 meters\]) at rest) * Use of any cytotoxic/immunosuppressive agent (other than prednisone ≤ 12.5 mg/day or equivalent) including, but not limited to, azathioprine, cyclophosphamide, methotrexate and cyclosporine within 4 weeks of screening * Use of any cytokine modulators: * Use of any biologic agent (such as etanercept, adalimumab, efalizumab, infliximab, golimumab, certolizumab) within 12 weeks or five half-lives of screening, and in the case of rituximab, use within 24 weeks of screening or no recovery of CD 19-positive B lymphocytes if the last dose of rituximab has been more than 24 weeks prior to screening * Alefacept within 24 months of randomization * Use of any therapy targeted to treat IPF (including but not limited to d-penicillamine, endothelium receptor antagonist \[eg bosentan, ambrisentan\], interferon gamma-1B, pirfenidone) within 4 weeks of screening * Use of n-acetylcysteine (NAC) for IPF (≥1800 mg/day) within 4 weeks of screening * Use of any investigational drug within one month of screening, or 5 PD/PK half lives, if known (whichever is longer) * Current smoker